A team led by Professor Mi Hee Lim of KAIST reported that a fragment of a zinc finger protein, a molecule better known for regulating genes, can interfere with the clumping of amyloid-beta, the peptide linked to Alzheimer's disease. The fragment, called ZF2-4, binds directly to the regions of amyloid-beta that drive it to aggregate. In test-tube experiments, this changed the aggregates that formed: the long, tangled toxic fibrils were suppressed and less harmful clumps appeared instead. When the researchers treated fibrils that had already formed, they broke into short, thin pieces and became less toxic to cells.
The harder problem was getting the protein into the brain. The blood-brain barrier keeps most large molecules out, so the team attached a short peptide to ZF2-4 to help it cross, producing a variant they named ZF2-4-P9. In a transgenic mouse model of Alzheimer's, this variant reduced amyloid-beta deposits by about 53 percent in both the cerebral cortex and the hippocampus, a region central to memory. It also lowered excessive activation of microglia, the brain's immune cells, by about 29 percent in the cortex and about 50 percent in the hippocampus.
Behavioral results were mixed. Treated mice performed better on a recognition memory task, distinguishing a familiar object from a new one, but the researchers reported no statistically significant gains on other memory and learning tests.
The authors frame the work as a proof of principle: engineering a protein's surface and structure can help control the aggregation of disease-related proteins, and the approach could inform protein-based therapeutics aimed at amyloid-beta. The researchers state that further studies are needed to evaluate therapeutic efficacy and long-term safety before any application in humans. The findings were published online in Advanced Science.